{
    "clinical_study": {
        "@rank": "167989", 
        "arm_group": [
            {
                "arm_group_label": "1000 mg EFB0026", 
                "arm_group_type": "Active Comparator", 
                "description": "BID"
            }, 
            {
                "arm_group_label": "1000 mg EFB0027", 
                "arm_group_type": "Experimental", 
                "description": "BID"
            }, 
            {
                "arm_group_label": "500 mg EFB0027", 
                "arm_group_type": "Experimental", 
                "description": "BID"
            }, 
            {
                "arm_group_label": "500 mg EFB0026 + 1000 mg EFB0027", 
                "arm_group_type": "Experimental", 
                "description": "BID"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate how EFB0027 and EFB0026 behave in subjects with type 2 diabetes\n      mellitus.\n\n      In addition, this study will compare the effects of EFB0027 and EFB0026 on circulating\n      concentrations of glucose and gastrointestinal hormones in subjects with type 2 diabetes\n      mellitus."
        }, 
        "brief_title": "Study Assessing the PK of EFB0027 and Effect on Circulating Glucose and GI Hormone Concentrations in Subjects With T2DM", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is 19 to 70 (inclusive) years old at Visit 1 (Screening).\n\n          2. Is diagnosed with Type 2 Diabetes Mellitus with\n\n               -  HbA1c between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with:\n\n                  i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at\n                  Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at\n                  Visit 1) of DPP-4 inhibitor alone, OR\n\n               -  HbA1c between 6.0 to 8.5% (inclusive) for subjects managing their diabetes with\n                  a stable (minimum of 2 months at Visit 1) combination regimen of metformin and\n                  DPP-4 inhibitors.\n\n          3. Has serum creatinine below the upper limit of normal at Visit 1 and an estimated\n             creatinine clearance above 80 using the Crockroft and Gault equation  (CrCl = [(140 -\n             age) x body weight in kg] / (serum creatinine x 72) x (0.85 for females) [ref. 3].\n\n          4. Has a body mass index (BMI) of 25.0 to 40.0 kg/m2 (inclusive) at Screening.\n\n          5. Is male, or is female and meets all of the following criteria:\n\n               -  Not breastfeeding\n\n               -  Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at\n                  Visit 1 (Screening) (not applicable to hysterectomized females)\n\n               -  Surgically sterile, postmenopausal, or if of childbearing potential, must\n                  practice and be willing to continue to practice appropriate birth control during\n                  the entire duration of the study\n\n          6. Has a physical examination with no clinically significant abnormalities as judged by\n             the investigator.\n\n          7. Ability to understand and willingness to adhere to protocol requirements.\n\n          8. If on chronic thyroid pharmacologic therapy, the dose must be stable for at least 3\n             months prior to Visit 1 (Screening), and must have thyroid-stimulating hormone (TSH)\n             test result in normal range at Visit 1 (Screening).\n\n        Exclusion Criteria:\n\n          1. Has a clinically significant medical condition that could potentially affect study\n             participation and/or personal well-being, as judged by the investigator, including\n             but not limited to the following conditions:\n\n               -  Hepatic disease\n\n               -  Renal disease\n\n               -  Gastrointestinal disease\n\n               -  Endocrine disorder except diabetes\n\n               -  Cardiovascular disease\n\n               -  Seizure disorder\n\n               -  Organ transplantation\n\n               -  Chronic infection\n\n          2. Has any chronic disease requiring medication that has been adjusted in the past 90\n             days (subjects may take acute intermittent over-the-counter medications such as\n             Tylenol, if needed).\n\n          3. Has any drug treatment that affects gastric pH (prescription or over-the-counter),\n             including any antacids or medications such as Rolaids or Pepcid within 2 days of\n             Visit 1 (Screening).\n\n          4. Has had major surgery of any kind within 6 months of Visit 1 (Screening).\n\n          5. Has received a blood transfusion within 6 months of Visit 1 (Screening).\n\n          6. Has a history of >5 kg weight change within 3 months of Visit 1 (Screening).\n\n          7. Has clinical laboratory test (clinical chemistry, hematology, or urinalysis)\n             abnormalities other than those expected in subjects with diabetes and judged by the\n             investigator to be clinically significant at Visit 1 (Screening).\n\n          8. Has physical, psychological, or historical finding that, in the investigator's\n             opinion, would make the subject unsuitable for the study.\n\n          9. Currently abuses drugs or alcohol or has a history of abuse that in the\n             investigator's opinion would cause the individual to be noncompliant with study\n             procedures.\n\n         10. Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate\n             blood during the study.\n\n         11. Has used insulin within 3 months of Visit 1 (Screening).\n\n         12. Has received GLP-1 receptor agonists and/or thiazolidinedione treatment within 6\n             months of Visit 1 (Screening).\n\n         13. Has known intolerance to metformin.\n\n         14. Has received any investigational drug within 1 month (or five half-lives of the\n             investigational drug, whichever is greater) of Visit 1 (Screening).\n\n         15. Has known allergies or hypersensitivity to any component of study treatment.\n\n         16. Is employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract\n             worker, or designee of the company).\n\n         17. Smokes more than 10 cigarettes per day, 2 cigars per day, or uses more than 1 can of\n             smokeless tobacco per week."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677299", 
            "org_study_id": "LCPOC10"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1000 mg EFB0027", 
                    "500 mg EFB0027", 
                    "500 mg EFB0026 + 1000 mg EFB0027"
                ], 
                "description": "Comparison of enteric-coating to assess effect on PK", 
                "intervention_name": "EFB0027", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1000 mg EFB0026", 
                    "500 mg EFB0026 + 1000 mg EFB0027"
                ], 
                "description": "Active comparator", 
                "intervention_name": "EFB0026", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 14, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tempe", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85283"
                    }, 
                    "name": "Celerion, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lincoln", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68502"
                    }, 
                    "name": "Celerion, Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Concentration of EFB0026 and EFB0027, measured in ng/mL", 
            "safety_issue": "No", 
            "time_frame": "-5, 15, 30, 60, 90, 120, 150, 180, 240, 360, 480,600, and 660 min relative to the start time of the standardized breakfast at Visits 3, 5, 7, and 9"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677299"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Elcelyx Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elcelyx Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}